NMN and NR: How Nicotinamide Mononucleotide and Riboside Affect Metabolism and Energy Expenditure

What NMN and NR Are and Why NAD+ Matters for Metabolism

NMN and NR are biosynthetic precursors to NAD+ (nicotinamide adenine dinucleotide), a coenzyme required for glycolysis, the citric acid cycle, oxidative phosphorylation, and the enzymatic activity of sirtuins and PARPs. Without adequate NAD+, mitochondrial electron transport slows and cellular energy sensing degrades. NAD+ levels fall with age, obesity, and metabolic disease, making repletion a logical metabolic target.

The Biosynthetic Pathways

NMN enters cells via the Slc12a8 transporter and is phosphorylated to NAD+ through the Preiss-Handler-adjacent NMNAT enzymes [1]. NR is phosphorylated to NMN first, then proceeds through the same NMNAT step [2]. Both routes bypass the rate-limiting enzyme NAMPT that constrains de novo NAD+ synthesis from tryptophan. This bypass is why oral supplementation reliably raises tissue NAD+ faster than dietary niacin at equivalent doses.

Why Aging Disrupts NAD+ Homeostasis

Skeletal-muscle biopsies from older adults show approximately 50% lower NAD+ content compared with young controls, a deficit linked to reduced NAMPT expression and increased CD38 NADase activity [3]. That depletion correlates with lower mitochondrial copy number, impaired fatty-acid oxidation, and reduced insulin-stimulated glucose uptake, forming the biochemical rationale for NMN/NR supplementation as a metabolic intervention.

NAD+ as an Energy-Sensing Hub

Sirtuins (SIRT1, SIRT3) deacylate histones and metabolic enzymes in a strictly NAD+-dependent manner [4]. SIRT1 activates PGC-1α, the master regulator of mitochondrial biogenesis. SIRT3 deacetylates and activates mitochondrial metabolic enzymes including complex I subunits and long-chain acyl-CoA dehydrogenase. When NAD+ falls below roughly 100 µM in mitochondria, sirtuin activity drops, mitochondrial protein acetylation rises, and oxidative capacity shrinks. Restoring NAD+ with NMN or NR re-engages this axis.

How Oral NMN and NR Raise NAD+ in Humans

Single-dose pharmacokinetics show that 500 mg of oral NMN raises whole-blood NAD+ by approximately 1.5-fold within 2 to 3 hours, returning to baseline by 8 hours [5]. Sustained dosing produces a steady-state elevation. A randomized, placebo-controlled trial by Yoshino et al. In Science (2021) gave 250 mg/day NMN for 10 weeks to 25 postmenopausal women with prediabetes and overweight or obesity [6]. Skeletal-muscle NAD+ increased significantly relative to placebo (P<0.05), confirming tissue-level repletion at a clinically practical dose.

NR Pharmacokinetics

For NR, a 2018 pharmacokinetic study by Trammel et al. (N=12) demonstrated that 1,000 mg of a single NR dose raised whole-blood NAD+ metabolome by roughly 2.7-fold over baseline within 6 hours [7]. At steady state (1,000 mg/day for 6 weeks), skeletal-muscle biopsies showed significant increases in NAD+ and related metabolites including NAAD and MeNAM, confirming that oral NR reaches peripheral tissues, not just blood [7].

Bioavailability Considerations

NMN and NR differ in gut handling. NR crosses intestinal epithelia intact via nucleoside transporters, while most circulating NMN is thought to be cleaved to NR before intestinal absorption, though this remains under active investigation [8]. Sublingual and liposomal NMN formulations are marketed as higher-bioavailability alternatives, but no head-to-head randomized trial has compared them to standard oral capsules on tissue NAD+ as a primary endpoint as of mid-2025.

The Yoshino 2021 Trial: Insulin Sensitivity and Skeletal-Muscle Metabolism

The most rigorous human metabolic trial published to date is Yoshino et al. In Science (2021) [6]. This 10-week, double-blind, randomized, placebo-controlled trial enrolled 25 postmenopausal women (mean age 59 years, mean BMI 32 kg/m²) with prediabetes. Participants received 250 mg/day oral NMN or placebo.

Primary Metabolic Findings

Hyperinsulinemic-euglycemic clamp testing showed that insulin-stimulated glucose disposal (Rd) increased significantly in the NMN group vs. Placebo. Insulin signaling in skeletal muscle improved, with higher phosphorylation of AKT and mTOR. The authors concluded that NMN "increased muscle insulin sensitivity, insulin signaling, and remodeling" [6]. Body weight did not change significantly, indicating the metabolic benefit was independent of weight loss.

Transcriptomics and Mitochondrial Gene Expression

Skeletal-muscle RNA sequencing revealed upregulation of 215 genes in the NMN group, including pathways governing mitochondrial biogenesis, oxidative phosphorylation, and fatty-acid metabolism [6]. Genes encoding complex I (NDUFB5) and complex III (UQCRB) subunits were among those increased, consistent with the sirtuin-PGC-1α axis outlined above. No adverse events differed significantly between groups.

What the Trial Does Not Show

Yoshino 2021 did not measure resting energy expenditure (REE) by indirect calorimetry, did not enroll men, and used a single dose (250 mg/day) for 10 weeks. Extrapolating the findings to long-duration weight management or thermogenesis in broader populations requires more evidence.

Effects on Energy Expenditure and Thermogenesis

Direct evidence that NMN or NR meaningfully raises resting energy expenditure in humans is limited. Animal data are more permissive: NMN administration in high-fat-diet mice raised oxygen consumption, activated brown adipose tissue, and prevented diet-induced obesity in a 2013 Cell Metabolism paper by Yoshino et al. [9]. That mechanistic work drove much of the clinical interest.

Human Indirect Calorimetry Data

A 2020 placebo-controlled trial by Dollerup et al. (N=40, obese men, NR 2,000 mg/day for 12 weeks) found no significant change in REE measured by indirect calorimetry, no change in body weight, and no change in fasting glucose [10]. Skeletal-muscle NAD+ did increase, confirming target engagement. The disconnect between NAD+ repletion and energy expenditure suggests that repletion alone may not overcome the full thermogenic deficit in metabolic disease.

Brown Adipose Tissue and SIRT3

SIRT3 deacetylates and activates uncoupling protein 1 (UCP1) in brown adipocytes, the molecular switch for non-shivering thermogenesis [11]. Raising NAD+ with NMN raises SIRT3 activity in rodent brown fat, increasing UCP1-mediated heat dissipation. Whether the same effect occurs in adult humans, who have limited metabolically active brown fat compared to rodents, has not been formally tested in a powered trial measuring brown adipose activity by PET-CT or thermography alongside NMN supplementation.

Exercise Interaction

A 2021 trial by Liao et al. (N=48 recreational runners, NMN 300 to 600 mg/day for 6 weeks) showed improved oxygen utilization efficiency (VO2 during submaximal running), with the 600 mg group showing the largest effect [12]. This suggests NMN may enhance aerobic metabolic efficiency during exercise rather than raising basal thermogenesis, a distinction with practical implications for prescribing context.

Mitochondrial Function: What Human Biopsies Show

The clearest human evidence for NMN/NR effects on mitochondria comes from skeletal-muscle biopsy studies. Beyond Yoshino 2021 [6] and Trammel 2018 [7], a 2020 trial by Elhassan et al. (N=12, older adults, NR 1,000 mg/day for 3 weeks) found significant increases in muscle NAD+ metabolome and a trend toward higher maximal mitochondrial respiration (State 3 OCR) in permeabilized fibers, though the sample size limited statistical power [13].

SIRT1 and PGC-1α Activation

Skeletal-muscle SIRT1 activity is directly proportional to intracellular NAD+ concentration in the physiological range [4]. When NMN or NR raises NAD+ above a threshold of approximately 200 to 300 µM in cytosol, SIRT1 deacetylates PGC-1α, which translocates to the nucleus, induces TFAM (mitochondrial transcription factor A), and drives replication of mitochondrial DNA [14]. This cascade is well-characterized in cell culture and rodent models. Human biopsy data from Yoshino 2021 showed increased expression of TFAM-dependent mitochondrial genes, providing indirect evidence of the same pathway operating in vivo [6].

Fatty-Acid Oxidation

SIRT3 also deacetylates and activates long-chain acyl-CoA dehydrogenase (LCAD), the rate-limiting enzyme in mitochondrial beta-oxidation [11]. In NMN-supplemented aged mice, hepatic and muscle fatty-acid oxidation rates increased by roughly 20 to 30% compared to vehicle-treated controls [9]. Corresponding human data on fat oxidation measured by respiratory quotient remain sparse, representing a clear gap for future trials.

Mitochondrial Biogenesis vs. Efficiency

Repletion of NAD+ may improve mitochondrial efficiency (lower proton leak, higher coupling efficiency) rather than simply increasing mitochondrial number. Dollerup et al. Measured mitochondrial respiration in muscle fibers from their NR trial and found no significant increase in biogenesis markers (citrate synthase activity), yet State 3 respiration trended upward [10]. This pattern is consistent with functional improvement in existing mitochondria rather than new organelle synthesis.

Clinical Dosing, Safety, and Practical Guidance

The table below summarizes the dosing ranges, durations, and populations studied in the major human trials to date. Clinicians considering NMN or NR for metabolic support should anchor expectations to these specific data points rather than extrapolating from rodent doses.

Dosing by Indication Context

For insulin sensitivity in postmenopausal women with prediabetes, Yoshino 2021 used 250 mg/day NMN for 10 weeks [6]. For whole-blood NAD+ repletion in healthy older adults, pharmacokinetic modeling suggests 500 to 1,000 mg/day NMN achieves sustained elevation [5]. For skeletal-muscle NAD+ metabolome in obese men, Dollerup et al. Used 2,000 mg/day NR for 12 weeks [10].

The Liao 2021 exercise trial used 300 and 600 mg/day NMN for 6 weeks and found a dose-dependent improvement in VO2 efficiency, with the 600 mg arm showing a statistically significant effect [12]. No trial has compared NMN directly to NR in a head-to-head randomized design on metabolic endpoints.

Safety Profile

No serious adverse events have been reported in randomized trials using NR up to 2,000 mg/day for 12 weeks or NMN up to 1,250 mg/day for 12 weeks [10, 15]. The most common adverse effects are mild gastrointestinal symptoms (nausea, flatulence) at higher doses. NOAEL (no-observed-adverse-effect level) in 28-day rat studies for NMN exceeds 1,500 mg/kg/day, providing a substantial safety margin at human supplemental doses [15].

A 2022 safety study by Yi et al. (N=80, healthy adults, NMN 300 to 900 mg/day for 60 days) found no clinically significant changes in hematology, liver enzymes, renal function, or lipid panels [15]. Fasting glucose and HbA1c were unchanged in this healthy cohort, consistent with a glucose-lowering effect confined to insulin-resistant populations.

Timing and Formulation

Morning dosing with food is used in most trials and is recommended to align with circadian NAD+ flux, which peaks during the active phase [16]. Splitting doses (e.g., 500 mg morning and 500 mg midday for a 1,000 mg/day regimen) may reduce GI side effects without sacrificing efficacy, though no formal bioequivalence trial has tested this.

Drug Interactions

NMN and NR are metabolized to NAD+, which is consumed by PARP enzymes during DNA repair. PARP inhibitors (olaparib, niraparib) could theoretically compete for NAD+ substrate. The interaction is theoretical at this time; no clinical pharmacokinetic study has characterized it in humans. Patients on PARP inhibitors should discuss NMN/NR use with their oncologist before starting.

Who May Benefit Most: Patient Selection

Based on current trial data, the populations most likely to show measurable metabolic benefit from NMN or NR are adults over 50 with reduced skeletal-muscle NAD+ due to aging, individuals with insulin resistance or prediabetes (fasting glucose 100 to 125 mg/dL or HbA1c 5.7 to 6.4%), and physically active adults seeking to improve aerobic metabolic efficiency [6, 12]. The evidence does not yet support NMN or NR as a first-line intervention for obesity, dyslipidemia, or cardiovascular risk reduction.

Patients with normal insulin sensitivity and no age-related NAD+ deficit (typically adults under 40 without metabolic disease) show smaller NAD+ responses to supplementation and no documented metabolic benefit in published trials. This ceiling effect is consistent with the biochemistry: repletion only matters when baseline NAD+ is genuinely depleted.